The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Germline mutations in POLE and POLD1 are linked to variable cancer risks, with findings highlighting mutation-specific differences that refine tumor predisposition assessment.
Following court injunctions, some states and cities regained funding, while others experienced continued cancellations that affected immunization clinics, workforce capacity, and infectious-disease surveillance.
Emails and interviews show CDC scientists were sidelined during the West Texas surge, leaving local officials without guidance as cases spread across the US and into Mexico.